D.E. Shaw & Co
IBRX icon

D.E. Shaw & Co’s ImmunityBio IBRX Stock Holding History

D.E. Shaw & Co’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.4M Buy
+12,571,597
New +$86.1M 0.06% 394
2025
Q3 		– Sell
-237,147
Closed -$626K – 4724
2025
Q2 		$626K Buy
+237,147
New +$638K ﹤0.01% 3535
2024
Q4 		– Sell
-520,053
Closed -$1.93M – 4591
2024
Q3 		$1.93M Buy
+520,053
New +$2.41M ﹤0.01% 2738
2024
Q2 		– Sell
-236,634
Closed -$1.27M – 4631
2024
Q1 		$1.27M Sell
236,634
-354,467
-60% -$1.61M ﹤0.01% 2930
2023
Q4 		$2.97M Buy
+591,101
New +$1.85M ﹤0.01% 2343
2022
Q4 		– Sell
-678,504
Closed -$3.37M – 4965
2022
Q3 		$3.37M Buy
678,504
+267,827
+65% +$1.22M ﹤0.01% 2505
2022
Q2 		$1.53M Buy
410,677
+315,409
+331% +$1.27M ﹤0.01% 3305
2022
Q1 		$534K Sell
95,268
-235,233
-71% -$1.44M ﹤0.01% 4328
2021
Q4 		$2.01M Sell
330,501
-46,969
-12% -$353K ﹤0.01% 3358
2021
Q3 		$3.68M Buy
377,470
+293,098
+347% +$3.23M ﹤0.01% 2416
2021
Q2 		$1.21M Buy
+84,372
New +$1.39M ﹤0.01% 3384
2020
Q4 		– Sell
-42,661
Closed -$296K – 4018
2020
Q3 		$296K Buy
+42,661
New +$425K ﹤0.01% 3450
2019
Q3 		– Sell
-13,200
Closed -$13K – 3899
2019
Q2 		$13K Sell
13,200
-1,508
-10% -$1.74K ﹤0.01% 3624
2019
Q1 		$23K Sell
14,708
-165,887
-92% -$208K ﹤0.01% 3536
2018
Q4 		$210K Buy
180,595
+139,431
+339% +$319K ﹤0.01% 3524
2018
Q3 		$152K Sell
41,164
-15,432
-27% -$48.8K ﹤0.01% 3589
2018
Q2 		$174K Buy
56,596
+15,787
+39% +$58.5K ﹤0.01% 3576
2018
Q1 		$159K Buy
40,809
+28,781
+239% +$126K ﹤0.01% 3360
2017
Q4 		$54K Buy
+12,028
New +$57K ﹤0.01% 3531

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co's IBRX Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in ImmunityBio (IBRX) in Q1 2026: 12,571,597 shares worth $96.4M. The stake represents 0.06% of the portfolio and ranks #394 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in IBRX as recently as Q2 2025.

D.E. Shaw & Co first reported a position in IBRX in Q4 2017 and has held it in 19 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • D.E. Shaw & Co held 12,571,597 shares of ImmunityBio worth $96.4M as of Q1 2026.
  • ImmunityBio was a new D.E. Shaw & Co position in Q1 2026.
  • ImmunityBio made up 0.06% of D.E. Shaw & Co's portfolio in Q1 2026, its #394 holding.
  • D.E. Shaw & Co first reported a position in ImmunityBio in Q4 2017 and has held it in 19 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.